logo
  

Cabot Microelectronics Names Scott Beamer CFO, Succeeding William Johnson

Cabot Microelectronics Corp. (CCMP), a supplier of chemical mechanical planarization polishing slurries, announced Tuesday the appointment of Scott Beamer as Vice President and Chief Financial Officer. He will succeed William Johnson, who plans to retire after almost 15 years in the role of CFO.

Beamer will assume his new role on January 15, 2018. Johnson will remain with the Company for a period of time to assist with a smooth transition.

The second largest CMP pads supplier to the semiconductor industry stated that Beamer joins the firm after more than four years as Vice President and Chief Financial Officer of Stepan Co. (SCL), a consumer and industrial products company.

Prior to Stepan, he held various senior finance roles over a 16-year career at PPG Industries, Inc., including serving as its CFO - Europe. Beamer began his career at Ernst & Young.

David Li, Cabot Microelectronics' President and Chief Executive Officer, said, ".... am confident his executive and financial expertise with worldwide, multi-billion dollar public companies in industries synergistic with ours will benefit our company greatly in significant areas. In addition, I want to thank Bill Johnson for his many important contributions to the growth and profitability of Cabot Microelectronics during his many years of service."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT